New 'bubble' targets only cancer cells

February 19, 2009

For millions of Americans with cancer, the side effects of chemotherapy and other treatment drugs can be devastating. But new drug-delivery research based on nano- and microtechnology from Tel Aviv University might provide much-needed relief, as well as more effective cancer treatment.

New drug delivery technology developed by Prof. Rimona Margalit of Tel Aviv University's Department of Biochemistry allows drugs to target cancer cells specifically, leaving surrounding healthy cells intact and reducing the painful side effects of chemotherapy. The science utilizes tiny bubbles, visible only through powerful microscopes, that contain payloads of therapeutic drugs.

"This development is on the leading edge of the new frontier of drug delivery and cancer treatment," says Prof. Margalit. "Bubble technology can also be applied to other medical conditions, including diabetes, osteoarthritis, wounds, and infectious diseases. In twenty years, it could be widespread."

Target: Cancer

Currently, cancer drugs travel throughout the body delivering powerful medication to all the cells they encounter, both healthy and cancerous. When healthy cells are damaged by unnecessary medication, a patient can experience unpleasant side effects ranging from hair loss to nausea. More worrying are further health risks due to the damage that the medication does to the patient's immune system.

Called "drug carriers" recent reports of Prof. Margalit's new technology applied in both cancer and osteoarthritis therapies were published in Nature Nanotechnology, and in the Journal of Controlled Release (2008). The technology allows cancer treatment medication to be placed inside tiny bubbles so small that millions fit along a single inch. The surface of the bubbles contains an agent that allows them distinguish cancer cells from healthy ones. When the bubbles "recognize" a cancer cell, they deliver the medication they're carrying to that cell.

The positive results are twofold: More of the drug gets directly to the cancer cells, enhancing the effectiveness of the treatment, and healthy cells continue to function normally, protected against the painful side-effects of the medication.

Economics, Not Science, Is Researchers' Next Challenge

Prof. Margalit's drug carrier technology has already performed well in animal model studies. The next step is to apply the technology to humans. "Economics is the hold-up, not the science," explains Prof. Margalit, who is in the process of finding a pharmaceutical company to invest in the research.

Although the technology is still a decade or more from clinical trials, this promising discovery offers new hope in oncology.

Source: American Friends of Tel Aviv University

Explore further: Colorful potatoes may pack powerful cancer prevention punch

Related Stories

Molecular machine, not assembly line, assembles microtubules

August 20, 2015

When they think about how cells put together the molecules that make life work, biologists have tended to think of assembly lines: Add A to B, tack on C, and so on. But the reality might be more like a molecular version of ...

Reprogramming the oocyte

August 26, 2015

(Phys.org)—Among other things, the egg is optimized to process the sperm genome. The cytoplasmic factors that make this possible also give the egg the ability to reprogram the nuclei from other kinds of cells if these nuclei ...

Recommended for you

Electrical circuit made of gel can repair itself

August 25, 2015

(Phys.org)—Scientists have fabricated a flexible electrical circuit that, when cut into two pieces, can repair itself and fully restore its original conductivity. The circuit is made of a new gel that possesses a combination ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.